Clinical Trial Update: Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II trial evaluating universal donor CD33 CAR natural killer cells for relapsed/refractory acute myeloid leukemia; the study status is NOT_YET_RECRUITI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Universal Donor CD33 CAR Natural Killer Cells (CD33 CAR NK cells)

Snippet

Sponsor: Nationwide Children's Hospital | Conditions: Relapsed/Refractory AML | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING